Company Description
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally.
The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, contract staffing, data solutions, and laboratory services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization.
In addition, the company offers testing services comprising bioanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers.
Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, medical imaging, real world intelligence, site and patient, and strategic solutions.
Additionally, it provides therapeutics for cardiovascular, central nervous system, endocrine and metabolic disorders, hepatology, infectious diseases, internal medicine immunology, and oncology.
It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations.
ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
| Country | Ireland |
| Founded | 1990 |
| IPO Date | May 15, 1998 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 40,100 |
| CEO | Barry Balfe |
Contact Details
Address: South County Business Park, Leopardstown Dublin, D18 X5R3 Ireland | |
| Phone | 353 1 291 2000 |
| Website | iconplc.com |
Stock Details
| Ticker Symbol | ICLR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001060955 |
| CUSIP Number | G4705A100 |
| ISIN Number | IE0005711209 |
| Employer ID | 98-1067160 |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Barry Balfe | Chief Executive Officer and Director |
| Dr. John Climax Ph.D. | Founder and Independent Non-Executive Director |
| Nigel Clerkin A.C.A. | Chief Financial Officer |
| Steve Empoliti | Chief Commercial Officer |
| Lyons Emer | Chief Accounting Officer |
| Thomas N. O'Leary | Chief Information Officer |
| Diarmaid Cunningham | Chief Administrative Officer, General Counsel and Company Secretary |
| Niamh Murphy | Director of Corporate Communications |
| David Green | Vice President of Marketing |
| Joe Cronin | Chief Human Resources Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 27, 2026 | 6-K | Report of foreign issuer |
| May 27, 2026 | 6-K/A | Filing |
| May 27, 2026 | 20-F | Annual and transition report of foreign private issuers |
| May 26, 2026 | 6-K | Report of foreign issuer |
| May 15, 2026 | SCHEDULE 13G | Filing |
| May 15, 2026 | SCHEDULE 13G/A | Filing |
| May 15, 2026 | SCHEDULE 13G/A | Filing |
| May 6, 2026 | SCHEDULE 13G | Filing |
| May 6, 2026 | SCHEDULE 13G | Filing |
| May 1, 2026 | NT 20-F | Notification of inability to timely file Form 20-F |